This inventor holds 3 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Medimmune Limited. Active years: 2018-2023.
Company Filing History:
Years Active: 2018-2023
Title: Michael Perkinton: Innovator in Antibody Research
Introduction
Michael Perkinton is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of antibody research, particularly in relation to alpha-synuclein. With a total of 3 patents, his work focuses on innovative solutions for treating diseases of the central nervous system.
Latest Patents
One of his latest patents is titled "Antibodies to alpha-synuclein and uses thereof." This invention provides antibodies that specifically bind human α-synuclein with a high affinity, reducing α-synuclein spreading in vivo. It also includes recombinant polypeptides comprising these antibodies or antigen-binding fragments, as well as methods for generating such polypeptides. Additionally, the patent outlines compositions and methods for generating α-synuclein antibodies, along with their applications in treating diseases of the central nervous system, particularly alpha-synucleinopathies.
Career Highlights
Michael Perkinton is currently associated with Medimmune Limited, where he continues to advance his research in antibody development. His work has been instrumental in understanding the mechanisms of alpha-synuclein and its implications in neurodegenerative diseases.
Collaborations
Some of his notable coworkers include Darren Schofield and Lorraine Irving. Their collaborative efforts contribute to the innovative research environment at Medimmune Limited.
Conclusion
Michael Perkinton's contributions to antibody research, particularly in relation to alpha-synuclein, highlight his role as a significant inventor in the field. His patents and ongoing work continue to pave the way for advancements in treating central nervous system diseases.